Вторичная медикаментозная профилактика ишемического инсульта


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

В статье обсуждаются вопросы вторичной профилактики ишемического инсульта, согласно данным доказательной медицины и международным рекомендациям. Пациентам, перенесшим преходящее нарушение мозгового кровообращения или ишемический инсульт, показаны контроль артериального давления и гликемии, применение антигипертензивных, липидкорригирующих и антитромботических (непрямых антикоагулянтов или антиагрегантов) препаратов.

Полный текст

Доступ закрыт

Об авторах

М. А Домашенко

НЦ неврологии РАМН

к.м.н., с.н.с.

М. Ю Максимова

НЦ неврологии РАМН

д.м.н., гл.н.с.

М. М Танашян

НЦ неврологии РАМН

д.м.н., профессор

Список литературы

  1. Гусев Е.И. Проблема инсульта в России // Журнал неврологии и психиатрии им. С.С. Корсакова 2003. № 9. С. 3-5.
  2. Инсульт. Принципы диагностики, лечения и профилактики / Краткое руководство для врачей/ Под ред. Н.В. Верещагина, М.А. Пирадова, З.А. Суслиной. М., 2002. 208 с.
  3. Парфенов В.А. Вторичная профилактика ишемического инсульта // РМЖ 2005. Т. 1. № 25. C. 819-23.
  4. Скворцова В.И., Чазова Е.И., Стаховская Л.В. Вторичная профилактика инсульта. М., 2002. 120 с.
  5. Сусли на З.А., Высоцкая В.Г. Антиагрегационное действие и клинический эффект малых доз аспирина при лечении больных с цереброваскулярной патологией на фоне артериальной гипертензии // Клиническая медицина 1983. № 9. C. 51-9.
  6. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 2006;367:1903-12.
  7. Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): A randomised controlled trial. Lancet Neurol 2007;6:115-24.
  8. Amarenco P, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
  9. American Diabetes Association. ADA clinical practice recommendations. Diabetes Care 2004;27:1-143.
  10. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
  11. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773-77.
  12. Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-28.
  13. Blanco M, et al. Statin treatment withdrawal in ischemic stroke: A controlled randomized study. Neurology 2007;69:904-10.
  14. CAPRIE Steering Committee. A randomized, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE): CAPRIE Steering Committee. Lancet 1996;348:1329-39.
  15. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
  16. Collins R, Armitage J, Parish S, et al. For the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
  17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
  18. Diener HC, Bogousslavsky J, Brass LM, et al. For the MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-37.
  19. Diener HC, Darius H, Bertrand-Hardy JM, et al. For the European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001;55:162-63.
  20. Dressler FA, et al. Mobile aortic atheroma and systemic emboli: Efficacy of anticoagulation and influence of plaque morphology on recurrent stroke. J Am Coll Cardiol 1998;31:134-38.
  21. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
  22. Echiverri HC, et al. Fusiform aneurysm of the vertebrobasilar arterial system. Stroke 1989;20:1741-47.
  23. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy: Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-59.
  24. Engelter ST, et al.Antiplatelets versus anticoagulation in cervical artery dissection. Stroke 2007;38:2605-11.
  25. Farrell B, Godwin J, Richards S, et al. The United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044-54.
  26. Flaker GC, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (spor-tif) trials. Am Heart J 2006;152:967- 73.
  27. Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1:1215-20.
  28. Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008 http://www.eso-stroke.org/recom-mendations.
  29. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack. Stroke 2011;42.
  30. Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989;321:501-7.
  31. Heart Protection Study Collaborative Group: Mrc/bhf heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
  32. Mohr JP, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
  33. Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 2011;365:883-91.
  34. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
  35. Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke 2003;34:2741-48.
  36. Ringleb PA, Bhatt DL, Hirsch AT, et al. for the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004;35:528-32.
  37. Schrader J, Luders S, Kulschewski A, et al. For the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003;34:1699-703.
  38. Schrier RW, Estacio RO, Esler A, et al. Effects of aggressive blood pressure control in nor-motensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 2002;61:1086-97.
  39. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20.
  40. The Dutch TIA trial: protective effects of low-dose aspirin and atenolol in patients with transient ischemic attacks or nondisabling stroke: the Dutch TIA Study Group. Stroke 1988;19:512-17.
  41. The European Stroke Prevention Study (ESPS): principal end-points: the ESPS Group. Lancet 1987;2:1351-54.
  42. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997;42:857-65.
  43. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38: UK Prospective Diabetes Study Group. BMJ 1998; 317:703-13.
  44. Visser CA, et al. Long-term follow-up of left ventricular thrombus after acute myo cardial infarction. A two-dimensional echo-cardiographic study in 96 patients. Chest 1984;86:532-36.
  45. Wilcox R, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: Results from proactive (prospective pioglitazone clinical trial in macrovascular events 04). Stroke 2007; 38:865-73.
  46. Yusuf S, Zhao F, Mehta SR, et al. For the-Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах